JP2023546536A - 線維症を処置する方法 - Google Patents

線維症を処置する方法 Download PDF

Info

Publication number
JP2023546536A
JP2023546536A JP2023547328A JP2023547328A JP2023546536A JP 2023546536 A JP2023546536 A JP 2023546536A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023546536 A JP2023546536 A JP 2023546536A
Authority
JP
Japan
Prior art keywords
fibrosis
gli1
lung
hydrogen
taladegib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546536A5 (enExample
Inventor
ロス リオス， ミゲル デ
ジョン フッド，
アニータ ディフランチェスコ，
Original Assignee
エンデバー バイオメディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンデバー バイオメディシンズ， インコーポレイテッド filed Critical エンデバー バイオメディシンズ， インコーポレイテッド
Publication of JP2023546536A publication Critical patent/JP2023546536A/ja
Publication of JP2023546536A5 publication Critical patent/JP2023546536A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023547328A 2020-10-13 2021-10-13 線維症を処置する方法 Pending JP2023546536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (2)

Publication Number Publication Date
JP2023546536A true JP2023546536A (ja) 2023-11-02
JP2023546536A5 JP2023546536A5 (enExample) 2024-11-14

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547328A Pending JP2023546536A (ja) 2020-10-13 2021-10-13 線維症を処置する方法

Country Status (8)

Country Link
US (4) US11628167B2 (enExample)
EP (1) EP4229828A4 (enExample)
JP (1) JP2023546536A (enExample)
KR (1) KR20230107568A (enExample)
CN (1) CN116349204A (enExample)
AU (1) AU2021360767A1 (enExample)
CA (1) CA3198661A1 (enExample)
WO (1) WO2022081661A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN116349204A (zh) 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
AU2024230449A1 (en) * 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530705A (ja) * 2009-06-19 2012-12-06 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (enExample) 1977-06-03 1981-03-07 Pfizer
ZA97288B (en) 1996-01-15 1998-07-14 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
CA2326654C (en) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
ES2505091T3 (es) 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
US7981892B2 (en) 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (en) 2008-08-04 2013-09-17 Amgen Inc. Aurora kinase modulators and methods of use
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
WO2015120257A2 (en) * 2014-02-06 2015-08-13 The Brigham And Women's Hospital, Inc. Uses of gli1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
JP2018535238A (ja) 2015-11-30 2018-11-29 イグナイタ インコーポレイテッド 局所製剤
CN109890390A (zh) * 2016-11-04 2019-06-14 上海瑛派药业有限公司 Hedgehog通路抑制剂在治疗纤维化疾病中的应用
CN112449602A (zh) * 2018-07-19 2021-03-05 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
CN116349204A (zh) * 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
AU2024230449A1 (en) 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530705A (ja) * 2009-06-19 2012-12-06 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORN, A. ET AL.: "Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of establish", ANNALS OF THE RHEUMATIC DISEASES, vol. 71, no. 5, JPN6025044078, 2012, pages 785 - 789, ISSN: 0005718012 *
UENO, H. ET AL.: "A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with", INVESTIGATIONAL NEW DRUGS, vol. 36, no. 4, JPN6025044079, 2018, pages 647 - 656, ISSN: 0005718011 *

Also Published As

Publication number Publication date
US11628167B2 (en) 2023-04-18
CA3198661A1 (en) 2022-04-21
US20240342170A1 (en) 2024-10-17
AU2021360767A9 (en) 2024-02-08
KR20230107568A (ko) 2023-07-17
US20230201195A1 (en) 2023-06-29
WO2022081661A1 (en) 2022-04-21
EP4229828A4 (en) 2024-08-28
US12295954B2 (en) 2025-05-13
US20220265650A1 (en) 2022-08-25
CN116349204A (zh) 2023-06-27
EP4229828A1 (en) 2023-08-23
AU2021360767A1 (en) 2023-04-27
US20250235452A1 (en) 2025-07-24
US12213974B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US12213974B2 (en) Methods of treating fibrosis
US12605377B2 (en) Methods of treating fibrosis
JP6170040B2 (ja) ピルフェニドン及び選択された患者における抗線維化療法
EP4673129A1 (en) Methods of treating fibrosis
JP2018501217A (ja) 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
JP2020529975A (ja) コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用
Kerstjens et al. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients
US20200368246A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
JP7794807B2 (ja) 気道疾患の治療に使用するための（１ｒ，３ｓ）－３－（（５－シアノ－４－フェニルチアゾール－２－イル）カルバモイル）シクロペンタン－１－カルボン酸およびその誘導体
Sugihara et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol
Hendeles et al. Response to inhaled albuterol during nocturnal asthma
CN120265291A (zh) 喹唑啉酮化合物的新用途和制剂
AU2023205787A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
TW200914455A (en) Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an analgesic effect, anti-allergic effect and histamine H1 receptor antagonism effect
TW202535397A (zh) 給藥方案
US20180228795A1 (en) Combination therapy for cancer
RU2804834C2 (ru) Применение мавоглуранта при снижении употребления кокаина или при предупреждении рецидива употребления кокаина
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
WO2026052068A1 (zh) 药物组合物的用途
WO2023108140A1 (en) Method of treating cancer having an activated hedgehog pathway
JP2005531622A5 (enExample)
WO2014130910A1 (en) Treatment for substance use disorders and stress disorders
WO2025240942A1 (en) Use of dexpramipexole for the treatment of eosinophilic copd
Liu The safety and necessity of Sugammadex in neuromuscular blockade reversal

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260430